Evercore ISI Group Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $37
Ultragenyx Pharmaceutical, Inc. +1.79%
Ultragenyx Pharmaceutical, Inc. RARE | 25.01 | +1.79% |
Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:
RARE) with a Outperform and lowers the price target from $39 to $37.
